<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

Parkinson's Disease

Unique approaches to modeling Parkinson's disease in preclinical models. 

 

Speak with a scientist

Complex Pathology

 

Parkinson’s Disease (PD) is typically an adult-onset progressive neurodegenerative movement disorder that affects millions of people worldwide. Pathologically, PD is characterized by the profound and specific loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. The cardinal symptoms of PD include bradykinesia, resting tremor, rigidity, and postural instability. To date, research into the etiology of PD has revealed that most cases are sporadic, though some thirteen genetic loci have been identified to be disease-related. Examination of the biochemical properties of these mutant proteins and the pathways in which they are involved has led to the uncovering of three basic pathogenetic pathways common to both heritable and idiopathic forms of PD: abnormal protein control, mitochondrial dysfunction, and altered kinase activity. 

 

Progress towards the identification of disease-related genes has thus led to the expansion of animal models of PD from the classic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA)-induced neurotoxin models to genetic models of the disease. Due to its complex pathology, however, there is no animal disease model that replicates all aspects of human PD. With the evolution of such models, converging lines of evidence from toxin-induced and genetic models have continued to further our understanding of the pathological processes underlying PD and lend themselves as useful systems for the examination of therapeutic interventions. 

 

Parkinson's Disease Models Offered

Speak with a scientist

Parkinson's Disease Staining

HC staining with Tyrosine Hydroxylase (TH) antibody. Staining of dopaminergic neurons, as TH is one of the enzymes involved in the production of Dopamine in neuronal cells.This staining is used in MPTP-induced PD model in mice or 6OHDA-induced PD model in rats.

Figure A. Subgross image of Substantia Nigra sections showing reduction in number of TH-positive cells in the right hemisphere vs. the left intact hemisphere. Figure B. High magnification of TH-positive dopaminergic neurons. Figure C. Subgross image of TH-positive nerve fibers in section of striatum of the Left intact hemisphere contrasted to the lack of TH staining in the right hemisphere injected with 6-OHDA.  

STAINING-6OHDA-SUBSTANTIA-NIGRA-MDBIOSCIENCES
 

READY TO DISCUSS YOUR PROGRAM?

If you are ready to discuss how a partnership can benefit your development program, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data.  

 

Request Proposal